Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: Yahoo! Finance
Upsized Oxford Finance debt facility extends cash runway and funds accelerated development through 2026 SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis (IPF). The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast's late-stage development compared to a traditional Phase 3 trial. Bexotegrast is an oral, small molecule, dual-selective inhibitor of avß6 and avß1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC). “The implementation of BEACON-IPF as an accelerated pivotal, adaptive Phase 2b/3 trial
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.MarketBeat
- Pliant Therapeutics to Participate in Upcoming Investor EventsGlobeNewswire
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceGlobeNewswire
- CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks [Yahoo! Finance]Yahoo! Finance
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- 3/12/24 - Form 8-K
- PLRX's page on the SEC website